|
Apr 2
|
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
|
|
Mar 21
|
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
|
|
Mar 20
|
Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials
|
|
Mar 20
|
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
|
|
Mar 13
|
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
|
|
Feb 29
|
private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week
|
|
Feb 28
|
Trevi Therapeutics to Participate in Upcoming March Events
|
|
Feb 6
|
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
|
Dec 5
|
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
|
|
Nov 30
|
Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)
|
|
May 2
|
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
|
|
Apr 27
|
Trevi Therapeutics to Participate in Upcoming May Investor Events
|